Clinical Trial Update: Myeloma-Developing Regimens Using Genomics (MyDRUG) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial named MyDRUG investigates genomics-guided regimens for relapsed or refractory multiple myeloma. The study has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: Multiple Myeloma Research Consortium | Conditions: Relapsed Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: COMPLETED